Léon Winkel
Research Subjects
Léon Winkel has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ma van Houten
Department of Pediatrics, Spaarne Hospital, Postbus 770, Hoofddorp 2130 AT, The Netherlands
1 shared publication - Marc J. M. Bonten
Department of Medical Microbiology, University Medical Center, Utrecht, The Netherlands
1 shared publication - Marie-Josee J. Mangen
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication - Mariet Felderhof
Department of Pediatrics, Spaarne Hospital, Postbus 770, Hoofddorp 2130 AT, The Netherlands
1 shared publication - Nico G. Hartwig
Department of Pediatric Infectious Diseases and Immunology, ErasmusMC–Sophia, Rotterdam, The Netherlands
1 shared publication - Patricia Bruijning-Verhagen
Julius Centre for Health Sciences and Primary Care, Department of Epidemiology, University Medical Centre Utrecht, Utrecht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 26 April 2013
- Published by Springer Nature in BMC Medicine
- Vol. 11 (1) , 112
Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination
The cost-effectiveness of universal rotavirus (RV) vaccination is controversial in developed countries. As a result, RV vaccination programs do not currently exist in most European countries. Hospitalization is the main driver of RV disease costs, and prematurity, low birth weight (LBW) and underlying medical conditions have been associated with RV hospitalization and complications. We investigated the cost-effectiveness of targeted RV vaccination of high-risk infants and universal RV vaccination versus no vaccination.
- 26 April 2013
- Published by Springer Nature in BMC Medicine
- Vol. 11 (1) , 112
Open AccessTargeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination
The cost-effectiveness of universal rotavirus (RV) vaccination is controversial in developed countries. As a result, RV vaccination programs do not currently exist in most European countries. Hospitalization is the main driver of RV disease costs, and prematurity, low birth weight (LBW) and underlying medical conditions have been associated with RV hospitalization and complications. We investigated the cost-effectiveness of targeted RV vaccination of high-risk infants and universal RV vaccination versus no vaccination.